| Patents for A61P 5 - Drugs for disorders of the endocrine system (28,908) |
|---|
| 10/10/2002 | CA2443050A1 Immunomodulation and effect on cell processes relating to serotonin family receptors |
| 10/10/2002 | CA2442532A1 Colloidal suspension of nanoparticles based on an amphiphilic copolymer |
| 10/10/2002 | CA2442525A1 Cyclopropylindole derivatives as selective serotonin reuptake inhibitors |
| 10/10/2002 | CA2442064A1 G-protein coupled receptors |
| 10/10/2002 | CA2442062A1 Secreted proteins |
| 10/10/2002 | CA2441252A1 Estrogen replacement therapy |
| 10/10/2002 | CA2438272A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 10/09/2002 | EP1246925A1 Di- or oligomer of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins |
| 10/09/2002 | EP1246847A2 Dna encoding a human melanin concentrating hormone receptor (mch1) and uses thereof |
| 10/09/2002 | EP1246842A1 Nk cell receptor polynucleotides, polypeptides, and antibodies |
| 10/09/2002 | EP1246828A1 Benzosulfones with calcium antagonist activity |
| 10/09/2002 | EP1246807A2 Novel hydantoin, thiohydantoin, pyrimidinedione and thioxopyrimidinone derivatives, preparation method and use as medicines |
| 10/09/2002 | EP1246792A1 Compounds and compositions for delivering active agents |
| 10/09/2002 | EP1246692A1 Templating of solid particles by polymer multilayers |
| 10/09/2002 | EP1246634A1 Methods for treating pancreatic disorders |
| 10/09/2002 | EP1246626A1 Use of a cyclic ether for the preparation of medicaments affecting glucose tolerance |
| 10/09/2002 | EP0944613B1 Benzopyran derivatives |
| 10/09/2002 | EP0833620B1 Fgfr3 as a marker for mesenchymal skeletal progenitor cells |
| 10/09/2002 | EP0783521B1 Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone |
| 10/09/2002 | EP0783310B1 Novel hormonal medicaments and use thereof for correcting oestrogen deficiencies |
| 10/09/2002 | CN1373660A Method for treating chronic pain using MEK inhibitors |
| 10/09/2002 | CN1372945A Magnetotherapeutic medicinal pad and its preparing process |
| 10/09/2002 | CN1092197C Bicyclic thiophene derivs, and use as gonadotropin releasing hormone antagonists |
| 10/08/2002 | US6462038 Such as 1,2,3,6-tetrahydro-1-methyl-9-(trifluoromethyl)-7h-(1,4)oxazino(3,2 -g)quinolin-7-one; nonsteroidal, high affinity and specificity antagonists and agonists or partial agonists, i.e. partial and/or tissue specific activators |
| 10/08/2002 | US6461602 Water-soluble, nontoxic prodrugs having a hydrolyzable carbamate group coupling the drug or active ingredient to a modified polymer; insoluble drug released in vivo; drug delivery |
| 10/03/2002 | WO2002077217A2 Human dual specificity protein phosphatase 7-like protein |
| 10/03/2002 | WO2002077028A1 Polypeptides and nucleic acids for bolekine |
| 10/03/2002 | WO2002076995A2 2-amino-propanol derivatives |
| 10/03/2002 | WO2002076979A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 10/03/2002 | WO2002076506A1 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
| 10/03/2002 | WO2002076494A2 USE OF CYTOKINES OF THE TGF-β SUPERFAMILY FOR THE TREATMENT AND DIAGNOSIS OF SKIN RELATED DISORDERS |
| 10/03/2002 | WO2002076476A2 Prodrugs of anticancer agents employing substituted aromatic acids |
| 10/03/2002 | WO2002076465A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent |
| 10/03/2002 | WO2002076462A1 Drugs for improving insulin resistance |
| 10/03/2002 | WO2002076450A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 10/03/2002 | WO2002076435A2 Lipid profile modulation with steroids |
| 10/03/2002 | WO2002076402A2 Fatty amine drug conjugates |
| 10/03/2002 | WO2001071004A3 Proteases |
| 10/03/2002 | US20020143149 Seven trans-membrane receptor-Fitz2 |
| 10/03/2002 | US20020143016 Administering to a patient suffering from anxiety a therapeutically or prophylactically effective amount of N-desmethylzopiclone, or a pharmaceutically acceptable salt, solvate, hydrate, or clathrate |
| 10/03/2002 | US20020143004 Allosteric adenosine receptor modulators |
| 10/03/2002 | US20020142983 MUC-1 antagonists and methods of treating immune disorders |
| 10/03/2002 | US20020142980 Nucleic acid molecules with novel chemical compositions capable of modulating gene expression |
| 10/03/2002 | US20020142962 Inhibition of abnormal cell growth with corticotropin-releasing hormone analogs |
| 10/03/2002 | US20020141945 Characteristic glass transition temperature (Tg) and a recommended storage temperature (Ts), glassy matrix and drug within the glassy matrix; unit dosage; stable dispersion over time |
| 10/03/2002 | CA2442178A1 2-amino-propanol derivatives |
| 10/03/2002 | CA2441890A1 Oestrogen and fatty acid monoester as a hypolipidaemic and antidiabetic agent |
| 10/03/2002 | CA2441824A1 Use of lipoaminoacids as absorption promoters in a pharmaceutical composition |
| 10/03/2002 | CA2441790A1 1,2,3,4-tetrahydroisoquinolines derivatives as urotensin ii receptor antagonists |
| 10/03/2002 | CA2441700A1 Polypeptides and nucleic acids for bolekine |
| 10/03/2002 | CA2441588A1 Use of cytokines of the tgf-.beta. superfamily for the treatment and diagnosis of skin related disorders |
| 10/03/2002 | CA2441092A1 Dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
| 10/02/2002 | EP1245565A1 Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them |
| 10/02/2002 | EP1244672A1 4-substituted 7-aza-indolin-2-ones and their use as protein kinase inhibitors |
| 10/02/2002 | EP1244649A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 10/02/2002 | EP1244626A2 Caspase inhibitors and uses thereof |
| 10/02/2002 | EP1244620A1 Cyclic amp-specific phosphodiesterase inhibitors |
| 10/02/2002 | EP1244617A1 Substituted aminoalkylamide derivatives as antagonists of follicle stimulating hormone |
| 10/02/2002 | EP1244471A1 Liquid composition of biodegradable block copolymer for drug delivery system and process for the preparation thereof |
| 10/02/2002 | EP1244427A2 Pharmaceutical compositions for oral administration |
| 10/02/2002 | EP1129091B1 Crf receptor antagonists and methods relating thereto |
| 10/02/2002 | DE10112925A1 Verwendung von Zuckerphosphaten, Zuckerphosphatanalogen, Aminosäuren, Aminosäureanalogen zur Modulation von Transaminasen und/oder der Assoziation p36/Malat Dehydrogenase Use of sugar phosphates, sugar phosphate analogs, amino acids, amino acid analogues for the modulation of transaminases and / or association of p36 / malate dehydrogenase |
| 10/02/2002 | DE10112825A1 HESylierung von Wirkstoffen in wässriger Lösung HESylation of drugs in aqueous solution |
| 10/02/2002 | CN1372570A Modified exendin and exendin agonists |
| 10/02/2002 | CN1372569A Keratinocyte growth factor-2 |
| 10/02/2002 | CN1372565A Non-aromatic estrogenic steroids with hydrocarbon substituent in position 11 |
| 10/02/2002 | CN1372555A Compositions and therapeutic mehtods involving isoflavones and analogues thereof |
| 10/01/2002 | US6458827 Adjustent of conformation equilibrium; active materials |
| 10/01/2002 | US6458805 Antagonists; especially sodium salts |
| 10/01/2002 | US6458791 Methods of treating muscle spasms using N-desmethylzopiclone |
| 10/01/2002 | US6458764 GRF analogs with increased biological potency |
| 10/01/2002 | US6458383 Pharmaceutical dosage form for oral administration of hydrophilic drugs, particularly low molecular weight heparin |
| 10/01/2002 | US6458338 Amino acid stabilized medicinal aerosol formulations |
| 10/01/2002 | CA2168113C Therapeutic peptide derivatives |
| 10/01/2002 | CA2063926C Imidazopyridine |
| 09/26/2002 | WO2002074913A2 Nucleic acid-associated proteins |
| 09/26/2002 | WO2002074808A2 Modified insulin with reduced immunogenicity |
| 09/26/2002 | WO2002074725A1 Novel ligands of nuclear receptor superfamily, process for producing the same and use thereof |
| 09/26/2002 | WO2002074346A2 Targeting chemical compounds to cells |
| 09/26/2002 | WO2002074327A2 Compositions and methods for treating gonadotrophin related illnesses |
| 09/26/2002 | WO2002074323A2 Using neural thread proteins to treat tumors and other hyperproliferative disorders |
| 09/26/2002 | WO2002074322A2 Human growth hormone for treating children with abnormal short stature and kits and methods for diagnosing gs protein dysfunctions |
| 09/26/2002 | WO2002074292A2 Hormone replacement therapy |
| 09/26/2002 | WO2002074291A2 Compositions useful for the treatment of pathologies responding to the activation of ppar-gamma receptor |
| 09/26/2002 | WO2002074056A2 Allosteric adenosine receptor modulators |
| 09/26/2002 | WO2002074045A2 Production of pancreatic islet cells and delivery of insulin |
| 09/26/2002 | WO2002062780A3 Phenoxy substituted benzocondensed heteroaryl derivatives as thyroid receptor ligands |
| 09/26/2002 | WO2002040484A3 Novel imidazole derivatives, production method thereof and use thereof |
| 09/26/2002 | WO2002022645A3 Method of making 7alpha-methyl-11beta-methoxy estradiol and related compounds with estrogenic activity |
| 09/26/2002 | WO2002000710A3 B7-like molecules and uses thereof |
| 09/26/2002 | WO2001098332A3 Secreted redox proteins |
| 09/26/2002 | WO2001095711A3 Transgenic mice containing nuclear hormone receptor gene disruptions |
| 09/26/2002 | WO2001070969A3 Regulation of human latrophilin-like g protein-coupled receptor |
| 09/26/2002 | WO2000061112A3 Solubilized pharmaceutical composition for parenteral administration |
| 09/26/2002 | WO1997019953A8 New lh-rh antagonists with improved effectiveness |
| 09/26/2002 | US20020137903 Sodium dependent glucose transporters found in the intestine and kidney (SGLT2); treating diabetes |
| 09/26/2002 | US20020137892 An isolated peptide transmitter-like receptor polypeptide with specific amino acid sequence or variant which has immunomodulatory, neuromodulatory and endocrinomodulatory activity |
| 09/26/2002 | US20020137798 Treatment of disorders secondary to organic impairments |
| 09/26/2002 | US20020137765 Sustained release formulations for growth hormone secretagogues |
| 09/26/2002 | US20020137749 Formulation for menopausal women |